{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:00:25Z","timestamp":1790161225955,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.xphs.2024.09.006","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T16:29:03Z","timestamp":1727195343000},"page":"3457-3469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunogenicity risk assessment of empty capsids present in adeno-associated viral vectors using predictive innate immune responses"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6146-0324","authenticated-orcid":false,"given":"Nicole","family":"Jarvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gorecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-2865","authenticated-orcid":false,"given":"Sathy V.","family":"Balu-Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xphs.2024.09.006_bib0001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"issue":"21","key":"10.1016\/j.xphs.2024.09.006_bib0002","doi-asserted-by":"crossref","first-page":"10346","DOI":"10.1128\/JVI.00841-06","article-title":"Host cell DNA repair pathways in adeno-associated viral genome processing","volume":"80","author":"Choi","year":"2006","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.006_bib0003","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Molecular Therapy"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.006_bib0004","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.xphs.2024.09.006_bib0005","unstructured":"ZOLGENSMA (onasemnogene abeparvovec-xioi) [package insert]. Novartis Gene Therapies, Inc.; 2019. https:\/\/www.fda.gov\/media\/126109\/download. Accessed July 10, 2023."},{"key":"10.1016\/j.xphs.2024.09.006_bib0006","unstructured":"LUXTURNA (voretigene neparvovec-rzyl) [package insert]. Spark Therapeutics, Inc.; 2017. https:\/\/www.fda.gov\/media\/109906\/download. Accessed July 10, 2023."},{"key":"10.1016\/j.xphs.2024.09.006_bib0007","unstructured":"HEMGENIX (etranacogene dezaparvovec-drlb) [package insert]. CSL Behring, LLC; 2022. https:\/\/www.fda.gov\/media\/163467\/download. Accessed July 10, 2023."},{"key":"10.1016\/j.xphs.2024.09.006_bib0008","unstructured":"BEQVEZTM (fidanacogene elaparvovec-dzkt) [package insert]. Pfizer, Inc.; 2024. https:\/\/www.fda.gov\/media\/178140\/download. Accessed June 03,2024."},{"key":"10.1016\/j.xphs.2024.09.006_bib0009","unstructured":"ELEVIDYS (delandistrogene moxeparvovec-rokl) [package insert]. Sarepta Therapeutics, Inc.; 2023. https:\/\/www.fda.gov\/media\/169679\/download. Accessed June 03, 2024."},{"key":"10.1016\/j.xphs.2024.09.006_bib0010","unstructured":"ROCTAVIAN (valoctocogene roxaparvovec-rvox) [package insert]. BioMarin Pharmaceutical Inc.; 2023. https:\/\/www.fda.gov\/media\/169937\/download. Accessed on July 10, 2023."},{"key":"10.1016\/j.xphs.2024.09.006_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.006_bib0012","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","article-title":"Early phase clinical immunogenicity of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A","volume":"29","author":"Long","year":"2021","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.006_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.xphs.2024.09.006_bib0014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7\u20138","key":"10.1016\/j.xphs.2024.09.006_bib0015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.xphs.2024.09.006_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.753467","article-title":"Adeno-associated viruses (AAV) and host immunity - a race between the hare and the hedgehog","volume":"12","author":"Rapti","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.xphs.2024.09.006_bib0017","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0019","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2\u2013mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.006_bib0020","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/CMR.00046-08","article-title":"Pathogen recognition and inflammatory signaling in innate immune defenses","volume":"22","author":"Mogensen","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.xphs.2024.09.006_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell Immunol"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.006_bib0022","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.006_bib0023","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"J Innate Immun"},{"key":"10.1016\/j.xphs.2024.09.006_bib0024","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-61779-012-6_16","article-title":"In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting","volume":"716","author":"Gaitonde","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"20","key":"10.1016\/j.xphs.2024.09.006_bib0025","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-04-215020","article-title":"GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-\u03b1 converting enzyme (TACE)","volume":"114","author":"Hiasa","year":"2009","journal-title":"Blood"},{"issue":"118","key":"10.1016\/j.xphs.2024.09.006_bib0026","doi-asserted-by":"crossref","DOI":"10.3791\/54968-v","article-title":"Generation of Human Monocyte-derived Dendritic Cells from Whole Blood","author":"Posch","year":"2016","journal-title":"J Vis Exp"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0027","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s43856-023-00413-7","article-title":"A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics","volume":"3","author":"Jarvi","year":"2023","journal-title":"Commun Med"},{"key":"10.1016\/j.xphs.2024.09.006_bib0028","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-4939-8885-3_7","article-title":"CD107a degranulation assay to evaluate immune cell antitumor activity","volume":"1884","author":"Lorenzo-Herrero","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2024.09.006_bib0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2004.08.008","article-title":"CD107a as a functional marker for the identification of natural killer cell activity","volume":"294","author":"Alter","year":"2004","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.xphs.2024.09.006_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23071700","article-title":"Understanding the role of anti-PEG antibodies in the complement activation by doxil in Vitro","volume":"23","author":"Neun","year":"2018","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.xphs.2024.09.006_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073595","article-title":"mRNA-LNP COVID-19 vaccine lipids induce complement activation and production of proinflammatory cytokines: mechanisms, effects of complement inhibitors, and relevance to adverse reactions","volume":"25","author":"Bakos","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.006_bib0032","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/gt.2008.65","article-title":"Manufacturing and characterizing AAV-based vectors for use in clinical studies","volume":"15","author":"Wright","year":"2008","journal-title":"Gene Ther"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.006_bib0033","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/d41573-021-00164-x","article-title":"Gene therapy community grapples with toxicity issues, as pipeline matures","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"10.1016\/j.xphs.2024.09.006_bib0034","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1182\/blood-2012-08-453738","article-title":"LAMP1\/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity","volume":"121","author":"Krzewski","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-immunol-101819-074948","article-title":"Natural killer cells: from innate to adaptive features","volume":"39","author":"Mujal","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.xphs.2024.09.006_bib0036","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fimmu.2017.00699","article-title":"Human CD56(dim)CD16(dim) cells as an individualized natural killer cell subset","volume":"8","author":"Amand","year":"2017","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.006_bib0037","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.006_bib0038","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/187152809788681038","article-title":"The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses","volume":"8","author":"Peng","year":"2009","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"10","key":"10.1016\/j.xphs.2024.09.006_bib0039","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ni1113","article-title":"The complement system in regulation of adaptive immunity","volume":"5","author":"Carroll","year":"2004","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.006_bib0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.006_bib0041","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jps.22276","article-title":"Impact of product-related factors on immunogenicity of biotherapeutics","volume":"100","author":"Singh","year":"2011","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0042","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/biomedicines2010080","article-title":"Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment","volume":"2","author":"Wright","year":"2014","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.006_bib0043","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.006_bib0044","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The balance between CD8(+) T cell-mediated clearance of AAV-encoded antigen in the liver and tolerance is dependent on the vector dose","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.006_bib0045","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG motifs in rAAV genomes: avoiding the toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.xphs.2024.09.006_bib0046","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.xphs.2024.09.006_bib0047","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.omtm.2021.08.009","article-title":"Comparison of analytical techniques to quantitate the capsid content of adeno-associated viral vectors","volume":"23","author":"Werle","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.006_bib0048","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11095-024-03678-2","article-title":"A high threshold of biotherapeutic aggregate numbers is needed to induce an immunogenic response In Vitro, In Vivo, and in the clinic","volume":"41","author":"Cohen","year":"2024","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.006_bib0049","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.006_bib0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/08982100009031112","article-title":"The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (DOXIL\u00ae)","volume":"10","author":"Szebeni","year":"2000","journal-title":"J Liposome Res"},{"issue":"9","key":"10.1016\/j.xphs.2024.09.006_bib0051","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.amjmed.2023.03.033","article-title":"The FDA modernization act 2.0: drug testing in animals is rendered optional","volume":"136","author":"Adashi","year":"2023","journal-title":"Am J Med"},{"key":"10.1016\/j.xphs.2024.09.006_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.006_bib0053","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1189\/jlb.0106011","article-title":"Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19","volume":"80","author":"Hoene","year":"2006","journal-title":"J. Leukoc. Biol"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.006_bib0054","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/000163501750266701","article-title":"Toll-like receptors and their signaling mechanism in innate immunity","volume":"59","author":"Kaisho","year":"2001","journal-title":"Acta Odontol Scand"},{"key":"10.1016\/j.xphs.2024.09.006_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2015.00021","article-title":"The immunoproteasome and viral infection: a complex regulator of inflammation","volume":"6","author":"McCarthy","year":"2015","journal-title":"Front Microbiol"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.006_bib0056","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/mt.2010.170","article-title":"Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application","volume":"18","author":"Monahan","year":"2010","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0057","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/mt.2009.257","article-title":"Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction","volume":"18","author":"Finn","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.006_bib0058","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/JVI.75.4.1824-1833.2001","article-title":"Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation","volume":"75","author":"Douar","year":"2001","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.006_bib0059","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/1566523220666200211111326","article-title":"Effect of proteasome inhibitors on the aav-mediated transduction efficiency in retinal bipolar cells","volume":"19","author":"Cui","year":"2020","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.xphs.2024.09.006_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970499","article-title":"Detection of innate immune response modulating impurities (IIRMI) in therapeutic peptides and proteins: impact of excipients","volume":"13","author":"Thacker","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.006_bib0061","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri1549","article-title":"Close encounters of different kinds: dendritic cells and NK cells take centre stage","volume":"5","author":"Degli-Esposti","year":"2005","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0062","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41598-019-40071-1","article-title":"Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity","volume":"9","author":"Rossi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2024.09.006_bib0063","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omtm.2019.05.012","article-title":"Enhancement of adeno-associated virus-mediated gene therapy using hydroxychloroquine in murine and human tissues","volume":"14","author":"Chandler","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.xphs.2024.09.006_bib0064","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3389\/fimmu.2019.01586","article-title":"Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5","volume":"10","author":"Brisse","year":"2019","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.xphs.2024.09.006_bib0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120474","article-title":"Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction","volume":"3","author":"Shao","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.006_bib0066","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nri.2016.116","article-title":"Dendritic cell migration in health and disease","volume":"17","author":"Worbs","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.006_bib0067","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.006_bib0068","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J Leukoc Biol"},{"issue":"12","key":"10.1016\/j.xphs.2024.09.006_bib0069","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming","volume":"5","author":"Mart\u00edn-Fontecha","year":"2004","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.xphs.2024.09.006_bib0070","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1172\/JCI122372","article-title":"Exposure to wild-type AAV drives distinct capsid immunity profiles in humans","volume":"128","author":"Kuranda","year":"2018","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.xphs.2024.09.006_bib0071","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/eji.202049028","article-title":"Human NK cells, their receptors and function","volume":"51","author":"Quatrini","year":"2021","journal-title":"Eur J Immunol"},{"issue":"208","key":"10.1016\/j.xphs.2024.09.006_bib0072","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006702","article-title":"Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry","volume":"5","author":"Horowitz","year":"2013","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.xphs.2024.09.006_bib0073","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.xphs.2024.09.006_bib0074","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr"},{"issue":"12","key":"10.1016\/j.xphs.2024.09.006_bib0075","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T10:01:29Z","timestamp":1734084089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0022354924004106"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.006","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity risk assessment of empty capsids present in adeno-associated viral vectors using predictive innate immune responses","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}